Amlodipine heart failure
Pro Research Analysisby 
Searched over 200M research papers
Amlodipine and Heart Failure: A Comprehensive Review
Introduction to Amlodipine in Heart Failure
Amlodipine, a calcium-channel blocker, has been extensively studied for its effects on heart failure, particularly in patients with severe chronic heart failure and nonischemic cardiomyopathy. This article synthesizes findings from multiple studies to provide a clear understanding of amlodipine's impact on heart failure outcomes.
Amlodipine's Impact on Morbidity and Mortality in Severe Chronic Heart Failure
General Findings
Research has shown that amlodipine does not significantly increase cardiovascular morbidity or mortality in patients with severe chronic heart failure. In a large-scale study involving 1153 patients, the primary endpoints of death from any cause and hospitalization for major cardiovascular events were reached by 42% of the placebo group and 39% of the amlodipine group, indicating a 9% reduction in the combined risk of fatal and nonfatal events with amlodipine .
Subgroup Analysis: Ischemic vs. Nonischemic Cardiomyopathy
Interestingly, the benefits of amlodipine appear to be more pronounced in patients with nonischemic cardiomyopathy. In this subgroup, amlodipine reduced the combined risk of fatal and nonfatal events by 31% and decreased the risk of death by 46% . However, no significant difference was observed in patients with ischemic heart disease .
Cytokine Modulation and Heart Failure Outcomes
Role of Cytokines
Amlodipine's beneficial effects in heart failure may be partially mediated by its impact on cytokine levels. In the PRAISE trial, amlodipine was found to significantly lower plasma levels of interleukin-6 (IL-6) after 26 weeks of treatment, although it did not significantly affect tumor necrosis factor-alpha (TNF-alpha) levels . Elevated IL-6 levels were associated with adverse events such as heart failure or death, suggesting that the reduction in IL-6 may contribute to the positive outcomes observed with amlodipine .
Long-Term Survival and Hospitalization Rates
Nonischemic Cardiomyopathy
In a study focusing on patients with severe heart failure due to nonischemic cardiomyopathy, amlodipine did not significantly reduce the risk of death or hospitalization compared to placebo over a median follow-up of 33 months . However, when data from this study were combined with an earlier trial, there was no evidence of a favorable or unfavorable effect of amlodipine on mortality .
Korean Nationwide Cohort Study
A large retrospective cohort study in Korea found that amlodipine use after hospitalization for heart failure in patients with dilated cardiomyopathy was associated with a significantly lower risk of all-cause death and heart failure rehospitalization over a 5-year period . This suggests that amlodipine may have long-term benefits in specific patient populations.
Mode of Death and Circadian Patterns
Cause-Specific Mortality
Amlodipine treatment resulted in a greater relative reduction in sudden deaths (21%) compared to pump failure deaths (6.6%) overall. In patients with nonischemic cardiomyopathy, both sudden deaths and pump failure deaths were significantly reduced with amlodipine .
Circadian Rhythm
Sudden deaths in advanced heart failure patients did not show the typical early morning peak associated with circadian sympathetic activation. Instead, a PM peak was observed, which was not affected by amlodipine treatment .
Exercise Tolerance and Quality of Life
Exercise Capacity and Hemodynamics
Studies have shown that amlodipine does not significantly improve exercise capacity, quality of life, or central and regional hemodynamics in patients with mild to moderate chronic heart failure 68. However, it does not increase the incidence of adverse events, suggesting it is safe for use in these patients .
Mechanisms of Action in Animal Models
Nitric Oxide Inhibition
In a murine model of congestive heart failure induced by viral myocarditis, amlodipine demonstrated a protective effect against myocardial injury, potentially through the inhibition of nitric oxide production . This suggests a possible mechanism for its beneficial effects in nonischemic cardiomyopathy.
Diastolic Heart Failure
Long-term administration of amlodipine in hypertensive rats prevented the transition to diastolic heart failure by attenuating myocardial stiffness and inhibiting collagen remodeling, indicating potential benefits in diastolic heart failure .
Conclusion
Amlodipine appears to offer specific benefits in heart failure, particularly in patients with nonischemic cardiomyopathy. While it does not significantly improve exercise capacity or quality of life, it may reduce mortality and hospitalization rates in certain populations. Further research is needed to fully understand its mechanisms and optimize its use in heart failure management.
Sources and full results
Most relevant research papers on this topic